^
    Back
    Association details:
    Biomarker:MTOR mutation
    Cancer:Germ Cell Tumors
    Drug:everolimus (mTOR inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    ASCO 2018
    Title:

    Comprehensive genomic characterization of chemotherapy-resistant testicular germ cell tumors (TGCT).

    Published date:
    05/16/2018
    Excerpt:
    Among pts with MTOR alterations, one Sem was treated based on genomic profiling and had an exceptional response to everolimus, after CT and immunotherapy (IT) failure
    DOI:
    10.1200/JCO.2018.36.15_suppl.4555